Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IL1B | P01584 | 9/20 | 0.59 |
| ▸ | NLRP3 | Q96P20 | 6/20 | 0.59 |
| ▸ | ACHE | P22303 | 3/20 | 0.56 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.51 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.51 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25798453 | 0.88 | NLRP3 (0.58) | IL1BNLRP3ACHECHRM2CHRM4 | |
| SCHEMBL25798526 | 0.88 | IL1B (0.66) | IL1BNLRP3ACHEKAT2B | |
| SCHEMBL25798125 | 0.84 | IL1B (0.67) | IL1BNLRP3 | |
| SCHEMBL25798268 | 0.84 | IL1B (0.62) | IL1BNLRP3HPGDRAB9ASMN1; SMN2 | |
| SCHEMBL25798371 | 0.82 | IL1B (0.62) | IL1BNLRP3 | |
| SCHEMBL25798059 | 0.79 | NLRP3 (0.65) | IL1BNLRP3ACHE | |
| SCHEMBL22654958 | 0.79 | IL1B (0.61) | IL1BNLRP3KAT2B | |
| SCHEMBL22654959 | 0.79 | IL1B (0.61) | IL1BNLRP3KAT2B | |
| SCHEMBL22655979 | 0.79 | IL1B (0.61) | IL1BNLRP3KAT2B | |
| SCHEMBL26772110 | 0.78 | IL1B (0.76) | IL1BNLRP3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023129987-A1 | PYRIDAZINE DERIVATIVES AS MODULATORS OF NLRP3 INFLAMMASOME AND RELATED METHODS | Neumora Therapeutics, Inc. (US) | 2023-07-06 | — | — | WO | disclosed |